Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024

Marker Therapeutics, Inc.

Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.
FDA cleared clinical protocol for MT-401 OTS in relapsed/refractory AML; inventory of 8 donor lines established.
Single donor could treat ~40 patients; product stable >1 year; first patient treatment expected H1 2024.
OTS strategy aims to reduce manufacturing cost and turnaround time to as little as 72 hours.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.